Cidara Therapeutics, Inc. (NASDAQ: CDTX ) is a biotech based in San Diego. They recently reported a major leap forward with their long-lasting flu prophylactic candidate, CD388. Since my February 2025 "Buy" rating, the company has updated us with exceedingly positive Phase 2bMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, ...